Genelux Corporation (GNLX)
Oxford Ledge is still expanding full research coverage of GNLX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Genelux develops oncolytic immunotherapies using engineered vaccinia virus, with its lead candidate in late-stage clinical trials.
SEC filings
- 8-K Shareholder vote results 2026-06-22
- 10-Q Quarterly financial report (unaudited) 2026-05-07
- DEF 14A Proxy statement for shareholder vote 2026-04-29
- 8-K Entry into material agreement; Financial statements and exhibits 2026-03-19
- 10-K Annual financial report with audited statements 2026-03-19
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for GNLX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open GNLX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.